All News

In a MET-unselected population of PD-L1–positive non–small cell lung cancer, the addition of capmatinib to pembrolizumab did not lead to more responses but increased toxicity.

The ATHENA-MONO trial showed a significant improvement in progression-free survival when patients with platinum-sensitive ovarian cancer were treated with maintenance rucaparib vs placebo in the first-line setting, regardless of HRD status.

The results, however, showed that remaining on mobocertinib may be warranted for patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer that has progressed after mobocertinib treatment.

Preliminary findings of data from the phase 1/2 LUPER study demonstrate that treatment with lurbinectedin combined with pembrolizumab elicits promising efficacy in patients with metastatic small-cell lung cancer that has failed to respond to chemotherapy.

Patients with TRK fusion–positive central nervous system tumors were observed to have increased efficacy and safety when treated with larotrectinib at long-term follow-up.

Subgroup analysis of the RE-MIND trial support use of tafasitamab plus lenalidomide to treat high-risk diffuse large B-cell lymphoma.

Biagio Ricciuti, MD, spoke about patients with non–small cell lung cancer with a very high PD-L1 tumor proportion score of 90% or more who were treated with first-line pembrolizumab monotherapy.

Data presented at 2022 ASCO reveals PET-imaging characteristics linked with 177Lu-PSMA-617 efficacy in metastatic castration-resistant prostate cancer.

Results of the ENZAMET trial presented at 2022 ASCO continue to support use of enzalutamide in patients with metastatic hormone-sensitive prostate cancer.

Distant metastasis-free and recurrence-free survival were better in patients with resected stage II melanoma who were treated with adjuvant pembrolizumab vs placebo.

Ifosfamide leads to slightly better event-free and overall survival vs topotecan/cyclophosphamide in relapsed or refractory Ewing sarcoma.

Without regard for tumor histology, NRG1-positive cancers treated with zenocutuzumab experienced promising efficacy and acceptable safety.

The addition of tiragolumab to atezolizumab plus carboplatin and etoposide did not yield improved overall survival or progression-free survival rates in patients with extensive-stage small cell lung cancer.

Alpelisib combined with fulvestrant represents a viable treatment option for patients with hormone receptor–positive, HER2-negative advanced breast cancer, regardless of mutation status.

Similar overall survival, better patient-reported outcomes, and fewer adverse effects were observed when patients were treated with 177Lu-PSMA-617 vs cabazitaxel in metastatic castration-resistant prostate cancer.

The phase 2 PILOT study showed encouraging overall response rates with lisacabtagene maraleucel in the second-line or beyond setting among patients with relapsed/refractory large B-cell lymphoma who did not receive hematopoietic stem cell transplantation.

Transplant following lenalidomide, bortezomib, and dexamethasone with lenalidomide maintenance was superior to the treatment course without transplant, according to data at 2022 ASCO.

The phase 3 DESTINY-Breast04 trial using fam-trastuzumab deruxtecan-nxki showed a reduction in the risk of disease recurrence or death for patients with HER2-low, hormone receptor–positive metastatic breast cancer.

Superior efficacy was observed when patients with RAS wild–type metastatic colorectal cancer were treated with panitumumab plus chemotherapy vs bevacizumab in the first-line setting.

Across 3 clinical trials, investigators continued to observe durable responses with larotrectinib, which showed the importance of NTRK gene fusion testing in patients with various cancer types.

Elderly frail patients with relapsed/refractory multiple myeloma treated with ixazomib plus daratumumab experienced favorable response rates.

Data from the phase 2 IFM 2018-04 trial support the use of daratumumab, carfilzomib, lenalidomide, and dexamethasone coupled with tandem autologous stem cell transplant in eligible patients with high-risk multiple myeloma.

Lenvatinib plus pembrolizumab decreased the risk of disease progression or death on second-line therapy by 50% compared with sunitinib in the phase 3 CLEAR trial.

Induction/consolidation daratumumab, lenalidomide, bortezomib and dexamethasone (RVd) outperformed RVd alone when it came to minimal residual disease and progression-free survival in patients with newly diagnosed, transplant-eligible myeloma.

A Claudin18.2–specific CAR T-cell therapy has shown promise in the treatment of patients with heavily pretreated advanced gastric and pancreatic adenocarcinoma whose disease expresses the marker.

Patritumab deruxtecan induced positive efficacy, according to the phase 1/2 U31402-J101 trial in patients with HER3-expressing metastatic breast cancer or metastatic triple-negative breast cancer.

At 2022 ASCO, final survival data from the phase 3 PALOMA-2 trial confirmed similar survival between palbociclib plus letrozole and letrozole alone.

Data on next line of therapy from the phase 3 Study 309/KEYNOTE-775 trial emphasized the benefit of lenvatinib plus pembrolizumab for advanced endometrial cancer.

Ribociclib plus endocrine therapy for hormone receptor–positive, HER2-negative advanced breast cancer following progression on a CDK4/6 inhibitor bests matched placebo.

Epcoritamab plus rituximab and lenalidomide yielded a 100% response rate in patients with relapsed or refractory follicular lymphoma.